Previous reports have shown the involvement of PU.1 in KMT2A-rearranged and FLT3-mutated AML as well as B-ALL pathogenesis [15,17,18], and targeting PU.1 has been shown to be an effective therapeutic approach for AML treatment [30]. The gene discussed is FLT3; the disease is acute myeloid leukemia.